On December 28, the innovative COVID-19 drug Taizhongding® developed by Guangsheng Zhonglin Technology Co., Ltd. (hereinafter referred to as Guangsheng Zhonglin), an innovative drug subsidiary of Fujian Guangshengtang Pharmaceuticals, was exclusively launched on the Meituan drug purchase online . It is understood that Taizhongding® is currently the only small molecule antiviral drug in China that widely covers the XBB series of mutant strains. The relevant person in charge of Fujian Guangshengtang Pharmaceutical stated that they chose Meituan Medicine as the online launch channel for Taizhongding® because they hope to cooperate with Meituan Medicine to further enhance the awareness and accessibility of innovative drugs. Give patients in need more treatment options.

Search volume for COVID-19 drugs increases, domestic innovative drugs provide new solutions for patients

Recently, the new coronavirus variant JN.1 has once again attracted public attention. Authoritative data shows that in early November this year, JN.1 accounted for about 4% of the global epidemic of viruses, rising to about 30% in early December. In addition, some experts predict that there may be a wave of new coronavirus infection peaks around New Year’s Day. This wave of infection may last until mid-to-late January 2024.

On November 23, Guangsheng Zhonglin developed the 3CL new coronavirus oral innovative drug Taizhongding® (generic name: atatetevir tablets/ritonavir tablets combination packaging) and has been approved for marketing. It is understood that compared with similar anti-new coronavirus oral drugs As a drug, Taizhongding® has lower daily dosage and high lung exposure. Phase III clinical trials cover the widest range of new coronavirus mutant strains, and the results show that it can quickly restore clinical symptoms; in terms of broad spectrum, all currently approved drugs in China have Among the batch of new coronavirus drugs, Taizhongding® is also the only anti-new coronavirus drug whose research has extensively covered the XBB series of mutant strains.

According to industry insiders, most of the new coronavirus drugs currently approved for marketing in China were approved earlier than the outbreak of the XBB variant strain. This means that the previously approved drugs were not included in this part of the clinical research. Currently, in response to new mutant strains, in addition to rapid antigen detection, early initiation of antiviral treatment is the optimal solution.

The relevant person in charge of Fujian Guangshengtang Pharmaceutical said that this time Taizhongding® was launched on Meituan Medicine, and they also hope to use the innovative marketing methods of Meituan Medicine’s digital platform to further enhance the awareness and accessibility of innovative drugs. .

Meituan’s drug-buying health index also shows that searches for new coronavirus drugs increased significantly across the country at the end of December. "We hope to provide users with a diverse supply of medicines." The person in charge of Meituan Medicine said that winter is the season with high incidence of respiratory diseases and influenza. This time, Meituan Medicine cooperated with Guangshengtang and Meituan delivered goods through express delivery of self-operated outpatient clinics to promote the launch of innovative drugs online. We hope to explore new ways for innovative drugs to be launched online, promote universal access to innovative drugs, and allow more patients to benefit from them.

"One-stop" becomes the "first stop", and new links for innovative drugs are launched online

For pharmaceutical companies, the research and development of new drugs has always been based on the saying of "two highs and one long". In addition to high investment and high risks in research, the drug will also face long-term tests on the channel and retail side when it is launched. How to cover a wider range of people in need through effective channels is also an important part of the launch of new drugs.

Based on the "digital helper" of brand pharmaceutical companies, Meituan Medicine can provide pharmaceutical companies with a full range of digital solutions in terms of digital retail distribution, omni-channel access to drug users, professional pharmacist services and online consultation. plan.

To this end, a large number of brand pharmaceutical companies have turned to online platforms for digital upgrades to reach drug users in a faster way. Taking Guangshengtang as an example, by cooperating with Meituan to buy medicines for online launch, it can not only realize online live streaming of famous doctors for patient education, but also rely on the one-stop health management path of Meituan to buy medicines to help users obtain professional health management efficiently. support.

It is understood that Meituan Medicine has reached cooperation with many industrial pharmaceutical companies such as China Resources Sanjiu, Harbin Pharmaceuticals, and Pfizer to provide them with comprehensive digital services and has become the preferred platform for many pharmaceutical companies to launch new drugs online. "We will continue to improve one-stop health management services, while providing users with more high-quality products and services, while also creating greater value for partners." said the person in charge of Meituan Medicine.

https://tech.caijing.com.cn/20231228/4980960.shtml